论文部分内容阅读
近年来,商品干扰素的开发主要集中在α干扰素,但最近的一项临床试验结果可能重新引起人们对β干扰素的兴趣。日本的一项初步临床试验发现,天然β干扰素能消除急性丙型肝炎病人中的丙型肝炎病毒。日本千叶大学医学院的研究人员报道,他们用Toray Industries公司生产的平均52兆单位的β干扰素对11例丙型肝炎病人平均治疗30天。1年后,仅4例病人的血清转氨酶水平仍持续较高,他们接受了第2疗程的治疗。再过2年,仅1例病人仍有较高水平的转氨酶。研究期间,12例对照病人中只有3例转氨酶水平下降。对病人检测血液中的丙型肝炎病毒RNA时获得类似结果。为期3年的研究结束后,11例接受治疗的病人中仅1例检出病毒RNA;而12例未治疗的病人中有11例检出病毒RNA。
In recent years, the development of commercial interferon has focused on interferon alpha, but the results of a recent clinical trial may reroute interest in beta interferon. A preliminary Japanese study found that natural beta interferon eradicated the hepatitis C virus in acute hepatitis C patients. Researchers at Japan’s Chiba University School of Medicine reported that they treated 11 hepatitis C patients for an average of 30 days with an average of 52 megabit interferon beta produced by Toray Industries. After 1 year, only 4 patients continued to have elevated levels of serum aminotransferases, receiving treatment for the second course of treatment. In another two years, only 1 patient still had a higher level of transaminase. During the study, only 3 of 12 control patients had decreased transaminases. Similar results were obtained when the patient tested hepatitis C virus RNA in the blood. After a three-year study, only 1 out of 11 treated patients detected viral RNA; 11 out of 12 untreated patients detected viral RNA.